Investigational Drug Information for GSI-136
✉ Email this page to a colleague
What is the development status for investigational drug GSI-136?
GSI-136 is an investigational drug.
There have been 13 clinical trials for GSI-136.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2002.
The most common disease conditions in clinical trials are Alzheimer Disease, Osteosarcoma, and Neoplasms. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, National Cancer Institute (NCI), and Baylor College of Medicine.
Summary for GSI-136
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2002-03-01) |
| Vendors | 7 |
Recent Clinical Trials for GSI-136
| Title | Sponsor | Phase |
|---|---|---|
| Nirogacestat in Ovarian Granulosa Cell Tumors | SpringWorks Therapeutics, Inc. | Phase 2 |
| EEG Changes in Pediatrics With Language Dysfunction Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. EEG Changes in Pediatrics With Language Dysfunction | Ain Shams University | Phase 3 |
| Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen | Azienda Ospedaliera San Paolo | Phase 3 |
Clinical Trial Summary for GSI-136
Top disease conditions for GSI-136
Top clinical trial sponsors for GSI-136
US Patents for GSI-136
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
